Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic shares are down today after the company announced mixed voting results from the U.S. FDA's Circulatory System Devices Panel on its Symplicity Spyral renal denervation system. Wall Street analysts are torn over whether the device will ultimately receive FDA approval.

Why Medtronic Stock Dropped Today

Medtronic's Q1 2024 earnings show 6% annual growth in revenues and EPS, marking a third consecutive quarter of mid-single-digit growth. The company's use of AI-driven tools and services, as well as innovative products, has contributed to growth across all divisions. Issues in Russia and China slowed growth slightly. Medtronic's diabetes division faces competition from new weight loss drugs, but the launch of its latest MiniMed device may help gain market share from rivals.

Medtronic Q1 2024 Earnings Review: Management Placates The Market

Medtronic PLC shares MDT, -0.05% were down 1.3% premarket on Thursday after advisors to the U.S. Food and Drug Administration had a mixed reaction to the company's investigational renal denervation system, used to treat high blood pressure. In a close vote, the advisory committee said the benefits of the system, Symplicity Spyral, did not outweigh the risks, although the panel voted favorably on the system's safety and effectiveness.

Medtronic shares fall after FDA advisors' lukewarm vote on blood-pressure treatment device

DUBLIN , Aug. 23, 2023 /PRNewswire/ -- Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System. The panel Committee voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the Symplicity blood pressure procedure.

Medtronic issues statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

The U.S. Food and Drug Administration's independent experts on Wednesday narrowly voted against recommending the approval of Medtronic's blood pressure treatment device, saying risks tied to using it do not outweigh the benefits.

US FDA panel votes against use of Medtronic's blood pressure treatment device

Insulet

Investors interested in Medical - Products stocks are likely familiar with Medtronic (MDT) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?

MDT or PODD: Which Is the Better Value Stock Right Now?

Abercrombie & Fitch

General Mills

Marvell Technology

NVIDIA

Constellation Brands

Dutch Bros

Netflix

Charles Schwab

Toll Brothers

Urban Outfitters

Here are some of the tickers on my radar for Wednesday, Aug. 23, taken directly from my reporter's notebook.

Here are 13 stocks Jim Cramer is watching, including a big retailer earnings winner

Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)

DUBLIN , Aug. 22, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today confirmed its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference Wednesday, September 6, 2023, at 12:00 p.m. EDT (11:00 a.m.

Medtronic to participate in upcoming investor conferences

The medical device maker unveiled its results for the first quarter of fiscal 2024. It topped analyst estimates for both revenue and adjusted profitability.

Why Medtronic Stock Was a Winner Today

Medtronic plc (NYSE:MDT ) Q1 2024 Earnings Call Transcript August 22, 2023 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head of IR Geoff Martha - Chairman and CEO Karen Parkhill - CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Mike Marinaro - EVP and President, Surgical and Endoscopy Sean Salmon - EVP and President, Cardiovascular Conference Call Participants Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Securities Danielle Antalffy - UBS Travis Steed - Bank of America Matt Miksic - Barclays Chris Pasquale - Nephron Jayson Bedford - Raymond James Joanne Weunsch - Citi Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning, I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations. I appreciate that you're joining us today for our Fiscal 2024 First Quarter Video Earnings Webcast.

Medtronic plc (MDT) Q1 2024 Earnings Call Transcript

Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Medtronic (MDT) Reports Q1 Earnings: What Key Metrics Have to Say

Medtronic topped quarterly expectations and raised its full-year outlook, giving MDT stock analyst confidence in the "long-term view."

Medtronic Beats Quarterly Expectations; Why It's Time To Embrace The 'Long-Term View'

Medtronic on Tuesday raised its annual profit forecast as the return of surgery volumes to pre-pandemic levels boosted demand for its medical devices, sending its shares up 3% in morning trading.

Medtronic says surgeries back at pre-pandemic levels, shares rise

Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals DUBLIN , Aug. 22, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2024 (FY24), which ended July 28, 2023. Key Highlights Revenue of $7.7 billion increased 4.5% as reported and 6.0% organic GAAP diluted earnings per share (EPS) of $0.59 decreased 16%; non-GAAP diluted EPS of $1.20 increased 6% Company increases FY24 organic revenue growth and EPS guidance Commenced U.S. launches of the MiniMed™ 780G system with Guardian™ 4 sensor in Diabetes and the Micra™ AV2 and Micra™ VR2 leadless pacemakers in Cardiovascular Financial Results Medtronic reported Q1 worldwide revenue of $7.702 billion, an increase of 4.5% as reported and 6.0% on an organic basis.

Medtronic reports first quarter fiscal 2024 financial results

Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Medtronic (MDT) Beat Estimates Again in Its Next Earnings Report?

The U.S. Food and Drug Administration (FDA) staff reviewers said on Friday they found no safety and effectiveness issues with devices made by Otsuka Holdings and rival Medtronic Plc for use in a blood pressure treatment surgery.

US FDA staff raise no concerns about Otsuka, Medtronic blood pressure devices

Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

DUBLIN , Aug. 17, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company's cash dividend for the second quarter of fiscal year 2024 versus the prior year, raising the quarterly amount to $0.69 per ordinary share. This quarterly declaration is consistent with the first quarter dividend announcement made by the company in May 2023.

Medtronic announces cash dividend for second quarter of fiscal year 2024

Medtronic is making changes to its business that could strengthen financial results. The company is looking at several important long-term growth catalysts.

3 Reasons to Buy Medtronic Stock

Enterprise Products Partners

There's always a reason not to invest, but sometimes you just need to act when you see a good opportunity.  Enterprise Products Partners is attractively priced, has a big yield, and has a highly reliable business.

Got $2,000? 2 Cheap Stocks to Buy Right Now

American Tower

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

Fulton Financial

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Philip Morris

TotalEnergies SE

Vanguard S&P 500 ETF

We received $941 in July dividend income. This was a 34.95% dividend increase compared to July 2022. One interesting benefit of moving the funds into VOO is that they pay dividends in an “off month” several times during the year. The Fulton July dividend has more than doubled since January and the Huntington dividend has grown over 50% in the same time period.

Bert's July 2023 Dividend Income Summary

Despite its soft guidance in May, Medtronic buyers didn't give up the $80 level. As such, I assessed that its worst is likely over as it bottomed in December 2022. The company is scheduled to report its first-quarter earnings release on August 22. Buying sentiment remains cautious, suggesting investors expect a relatively tepid scorecard. However, MDT is no longer overvalued and could outperform its cautious outlook if the market dynamics improve further.

Medtronic: Dark Clouds Are Clearing - Outperformance Ahead

AbbVie

Colgate-Palmolive

Schlumberger

Telefonica SA

Texas Instruments

There's a reasonable argument to be made that investors should load up on blue-chip stocks regularly. After all, large and well-established firms with long track records of success are likely to continue to be successful.

News for Medtronic Stock (MDT)